Skip to main content
2026 CRT Conference Main banner

Matthew D. Saybolt, MD

Medical Director, Structural Heart Disease Program
Hackensack Meridan Jersey Shore University Medical Center
Eatontown, New Jersey, United States

Matthew Saybolt, MD is the medical director of the structural heart disease program at Hackensack Meridian Jersey Shore University Medical Center and is an executive partner at Monmouth Cardiology Associates. He completed all of his training at the Hospital of the University of Pennsylvania. He remains an active principle investigator in several interventional and strucutural heart disease clinical trials and specializes in minimally invasive therapies for the treatment of valvular and structural heart disease. These include transcatheter aortic valve replacement (TAVR), transcatheter edge-to-edge mitral and tricuspid valve repair, closure of PFO and ASD, transcatheter valve in valve therapy, paravalvular leak closure and alcohol septal ablation. He also has ongoing clinical and research intrests in coronary physiology, intravascular imaging, and atherosclerotic plaque morphology.

Disclosure(s): Abbott Vascular,: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Boston Scientific: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Medtronic, Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Shockwave Medical: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

Presentation(s):

Email Matthew